have shown that promoters of the protein regulator of cytokinesis 1 (PRC1) and ribonuclease reductase 2 (RRM2) genes can be used in targeting breast cancer cells because these promoters exhibit strong gene expression similar to that driven by the CMV promoter.60 This evidence concerns the gene RRM2 and breast carcinoma.